Latest news for AIB Group (OTC:AIBGY) Stock

AIB Group PLC is a banking services company. The company's operating segments are Retail Banking; Capital Markets; AIB UK and Group. It generates maximum revenue from the Retail Banking segment. Retail Banking segment comprises Homes and Consumer, SME and Financial Solutions Group (FSG) in a single integrated segment, focused on meeting the current, emerging and future needs of personal and SME customers. Geographically, it derives a majority of revenue from Ireland and also has a presence in the United Kingdom and the Rest of the World.

News

Intraday Update

Markets

Movers

Trading Ideas

ABEV

ABIO

ABMD

ABVC

ACCYY

ACHV

ACIW

ACOR

ACRFF

ACRX

ACSAY

ACST

ADHC

ADMA

ADMP

AEGOF

AFLYY

AFRAF

AGCO

AGEEF

AHKSY

AHOTF

AIBGY

AIPUY

AKRX

ALDX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALLY

ALMFF

ALOT

ALSN

ALTM

ALXN

AMADY

AMCX

AMKBF

AMKBY

AMNP

AMPH

AMRH

AMRQQ

AMTX

ANAT

ANCN

ANGO

ANIP

ANZLY

APEX

APHA

APLE

APTS

AQARF

ARCB

ARCH

ARGGY

ARGO

ARLP

ARNA

ARNGF

AROC

ARREF

ARTL

ASNA

ASTVF

ATRA

ATRI

ATROB

ATSG

ATUSF

AUTL

Stocks That Hit 52-Week Lows On Thursday

Movers & Shakers

General

AACAY

AAWW

ABBV

ACGBF

ACRGF

AERI

AGTK

ALKM

ALNA

ALSWF

AMAG

ANGI

APGMF

APNHY

APOP

ARLO

ASRT

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHOF

ATVK

AVNS

AWLCF

AXGN

AXVEF

AZRX

AZZUF

BAFYY

BBCP

BBVA

BBVXF

BCDA

BCEFF

BCEL

BCYC

BDVSY

BEDU

BFIN

BHKLY

BICEF

BIDU

BIOAF

BIREF

BJRI

BKKLY

BKRIF

BKRIY

BLCM

BLMN

BLRX

BNDSF

BNEFF

BPAQF

BPFH

BRKMY

BRTX

BrightSphere Investment Group plc Ordinary Shares

BSIG

BTHE

BUDZ

BWFG

BXEFF

BZLFY

CADE

CAIXY

CAKE

CALX

CARB

CARCY

CARG

CARS

Stocks That Fell Through 52-Week Lows Wednesday

AIB Group PLC

Piper Sandler analyst Mark Lear maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and raises the price target from $247 to $249.

Price Target

Analyst Ratings

FANG

Piper Sandler Maintains Overweight on Diamondback Energy, Raises Price Target to $249

Guidance

Manpower Sees Q3 EPS Of $1.25 - $1.35 Vs. $1.36 Est.

Berkshire Hills Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.52 by 9.62 percent. This is a 3.64 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $88.53 million which missed the analyst consensus estimate of $90.50 million by 2.17 percent. This is a 4.56 percent decrease over sales of $92.76 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

BHLB

Berkshire Hills Bancorp Q2 Adj $0.57 Beats $0.52 Estimate, Sales $88.53M Miss $90.50M Estimate

Stephens &amp; Co. analyst Terry McEvoy maintains Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) with a Equal-Weight and raises the price target from $39 to $45.

EQBK

Stephens & Co. Maintains Equal-Weight on Equity Bancshares, Raises Price Target to $45

BWMN

Bowman Acquires FCS Group, Terms Not Disclosed; Co. Anticipates Deal Will Initially Contribute Annualized Net Service Billing Run Rate Of ~$7M And Be Immediately Accretive

Abbott Laboratories Q2 2024 Adj EPS $1.14 Beats $1.10 Estimate, Sales $10.377B Beat $10.371B Estimate

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $46 to $47.

Piper Sandler Maintains Overweight on EQT, Raises Price Target to $47

ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.28 by 1.56 percent. This is a 17.72 percent decrease over earnings of $1.58 per share from the same period last year. The company reported quarterly sales of $4.52 billion which met the analyst consensus estimate. This is a 6.92 percent decrease over sales of $4.86 billion the same period last year.

ManpowerGroup Q2 Adj $1.30 Beats $1.28 Estimate, Sales $4.52B Inline

OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.96 by 12.5 percent. This is a 16.13 percent increase over earnings of $0.93 per share from the same period last year.

OFG Bancorp Q2 2024 GAAP EPS $1.08 Beats $0.96 Estimate

Market-Moving Exclusives

Exclusives

LSTA

EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and raises the price target from $233 to $234.

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Raises Price Target to $234

Haystack Oncology, a Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>).
Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules.
Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors.
Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
In the FORTIFIDE study, Lisata is investigating the safety, tolerability, and efficacy of its lead product candidate, certepetide, when given as a 4-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer.
As part of this research, Lisata has engaged Haystack to use its MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide.
The American Cancer Society estimates more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024. mPDAC accounts for more than 90% of pancreatic cancer cases and is a highly aggressive form of the disease.
Most recently, Lisata Therapeutics announced the early completion of enrollment in its Phase 2a BOLSTER trial evaluating certepetide (formerly LSTA1), Lisata&#8217;s investigational product, as a treatment for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39790403/lisata-therapeutics-announces-completion-of-enrollment-in-its-phase-2a-bolster-trial-of-certepetid" rel="noreferrer noopener">first-line cholangiocarcinoma</a>.
Price Action: DGX shares closed at $148.48, and LSTA shares closed at $3.66 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/05/38842564/employers-struggle-with-drug-test-policies-amid-varying-state-laws-cheating-on-drug-tests-reaches-30" target="_blank" rel="noreferrer noopener">Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High</a>.</li>
</ul>

Biotech

Health Care

Contracts

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Stephens &amp; Co. analyst Terry McEvoy maintains Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) with a Equal-Weight and raises the price target from $90 to $110.

Stephens & Co. Maintains Equal-Weight on Nicolet Bankshares, Raises Price Target to $110

Lilium N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares are trading higher after it entered into a definitive sales agreement with Saudia Group or 50 Lilium Jets, with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39832573/saudia-group-signs-industry-leading-sales-agreement-with-lilium-to-acquire-up-to-100-evtol-jets" rel="noreferrer noopener">options for an additional 50 aircraft</a>.
Following the Memorandum of Understanding signed between Saudia Group and Lilium in October 2022, this sales agreement represents a significant milestone in the industry.
The deal marks the largest reported firm order of eVTOL aircraft in the MENA region by an airline committed to operating these aircraft.
The agreement details payment schedules, delivery timelines, performance guarantees, and provisions for spare parts and maintenance.
Additionally, the parties aim to finalize a &#8220;Lilium POWER-ON&#8221; agreement for fleet maintenance and support.
Saudia Group anticipates receiving its first jets in 2026, managed by its subsidiary, Saudia Private.
Lilium&#8217;s agreement with Saudia Group expands its order pipeline, comprising 106 firm orders and reservations, 76 options, and around 600 aircraft under MOU.
H.E. Engr. Ibrahim Al-Omar, Director General of Saudia Group,&nbsp;said,&nbsp;&#8220;This agreement amplifies our commitment to the Saudi Vision 2030 and is the result of a collaborative effort over the past years between Lilium and Saudia Group to explore how we can best bring eVTOL to the skies of Saudi Arabia.&#8221;
&#8220;Business travelers and exhibition attendees will benefit tremendously from the ease and speed of electric aircraft, allowing them to seamlessly attend and participate in events. These innovative vehicles will also be a game-changer for tourism, sports, and entertainment, offering a premium travel experience for these exciting destinations.&#8221;
Lilium is also in advanced discussions with global airlines committed to reducing carbon emissions and adopting electric regional air travel.
Yesterday, Lilium confirmed its 2026 delivery schedule for the first customer shipments, following a recent program review that includes testing, validation, and preparations for the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39812459/lilium-reaffirms-2026-target-for-first-customer-deliveries-and-provides-additional-detail-on-testi" rel="noreferrer noopener">first manned flight in early 2025</a>.
Price Action: LILM shares are up 2.98% at $0.9999 premarket at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Equities

Small Cap

LILM

Why Electric Aircraft Manufacturer Lilium Shares Are Surging Premarket Thursday

Piper Sandler analyst Mark Lear maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and raises the price target from $33 to $34.

Piper Sandler Maintains Neutral on APA, Raises Price Target to $34

JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and lowers the price target from $24 to $21.

JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

AIB Group

News

Latest news for AIB Group (OTC:AIBGY) Stock

Tuesday, March 24, 2020

Thursday, February 27, 2020

Wednesday, August 07, 2019